Rapid Micro Biosystems, Inc. (RPID) Financial Statements (2023 and earlier)
Company Profile
| Business Address |
1001 PAWTUCKET BLVD. LOWELL, MA 01854 |
| State of Incorp. | MA |
| Fiscal Year End | December 31 |
| Industry (SIC) | 3826 - Laboratory Analytical Instruments (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 6/30/2023 MRQ | 12/31/2022 | 12/31/2021 | |||
|---|---|---|---|---|---|
| ASSETS | |||||
| Current Assets | |||||
| Cash, cash equivalents, and short-term investments | 108,648 | 193,497 | |||
| Cash and cash equivalents | 27,064 | 178,387 | |||
| Short-term investments | 81,584 | 15,110 | |||
| Receivables | 5,369 | 5,005 | |||
| Inventory, net of allowances, customer advances and progress billings | 21,187 | 15,671 | |||
| Inventory | 21,187 | 15,671 | |||
| Prepaid expense | 1,500 | 1,622 | |||
| Contract with customer, asset, after allowance for credit loss | 112 | 396 | |||
| Deposits current assets | 1,055 | 1,262 | |||
| Other current assets | 705 | 440 | |||
| Other undisclosed current assets | 231 | ||||
| Total current assets: | 138,576 | 218,124 | |||
| Noncurrent Assets | |||||
| Finance lease, right-of-use asset, after accumulated amortization | 317 | ||||
| Operating lease, right-of-use asset | 6,746 | ||||
| Property, plant and equipment | 13,818 | 11,304 | |||
| Long-term investments and receivables | 29,790 | 9,966 | |||
| Long-term investments | 29,790 | 9,966 | |||
| Restricted cash and investments | 284 | 284 | |||
| Other noncurrent assets | 1,119 | 1,491 | |||
| Other undisclosed noncurrent assets | |||||
| Total noncurrent assets: | 52,074 | 23,045 | |||
| TOTAL ASSETS: | 190,650 | 241,169 | |||
| LIABILITIES AND EQUITY | |||||
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 13,578 | 14,861 | |||
| Accounts payable | 5,428 | 3,944 | |||
| Accrued liabilities | 8,150 | 10,917 | |||
| Deferred revenue | 4,706 | 3,305 | |||
| Debt | 37 | ||||
| Other undisclosed current liabilities | 729 | ||||
| Total current liabilities: | 19,050 | 18,166 | |||
| Noncurrent Liabilities | |||||
| Long-term debt and lease obligation | 304 | ||||
| Finance lease, liability | 304 | ||||
| Liabilities, other than long-term debt | 7,127 | 1,210 | |||
| Other liabilities | 229 | 1,210 | |||
| Operating lease, liability | 6,898 | ||||
| Other undisclosed noncurrent liabilities | 813 | ||||
| Total noncurrent liabilities: | 7,431 | 2,023 | |||
| Total liabilities: | 26,481 | 20,189 | |||
| Equity | |||||
| Equity, attributable to parent, including: | 164,169 | 220,980 | |||
| Additional paid in capital | 540,775 | 535,693 | |||
| Accumulated other comprehensive loss | (1,109) | (16) | |||
| Accumulated deficit | (375,918) | (315,112) | |||
| Other undisclosed equity, attributable to parent | 421 | 415 | |||
| Total equity: | 164,169 | 220,980 | |||
| TOTAL LIABILITIES AND EQUITY: | 190,650 | 241,169 | |||
Income Statement (P&L) ($ in thousands)
| 6/30/2023 TTM | 12/31/2022 | 12/31/2021 | ||
|---|---|---|---|---|
| Revenues | 17,133 | 23,232 | ||
| Cost of revenue | (25,596) | (30,991) | ||
| Gross profit: | (8,463) | (7,759) | ||
| Operating expenses | (54,756) | (39,473) | ||
| Operating loss: | (63,219) | (47,232) | ||
| Nonoperating income (expense) | 1,837 | (26,201) | ||
| Interest and debt expense | (42) | (3,100) | ||
| Loss from continuing operations before equity method investments, income taxes: | (61,424) | (76,533) | ||
| Other undisclosed income from continuing operations before income taxes | 42 | 3,100 | ||
| Loss from continuing operations before income taxes: | (61,382) | (73,433) | ||
| Income tax expense (benefit) | 576 | (91) | ||
| Loss from continuing operations: | (60,806) | (73,524) | ||
| Loss before gain (loss) on sale of properties: | ✕ | (73,524) | ||
| Net loss: | (60,806) | (73,524) | ||
| Other undisclosed net loss attributable to parent | ||||
| Net loss attributable to parent: | (60,806) | (73,524) | ||
| Preferred stock dividends and other adjustments | (4,508) | |||
| Net loss available to common stockholders, diluted: | (60,806) | (78,032) | ||
Comprehensive Income ($ in thousands)
| 6/30/2023 TTM | 12/31/2022 | 12/31/2021 | ||
|---|---|---|---|---|
| Net loss: | (60,806) | (73,524) | ||
| Comprehensive loss: | (60,806) | (73,524) | ||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | (1,093) | (17) | ||
| Comprehensive loss, net of tax, attributable to parent: | (61,899) | (73,541) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.